Caelyx/DoxilÒ) (see Table 1 for details of i.t. and i.v. treatments). She also received radiotherapy to the lower thoracic-lumbar spine. After the second dose of i.v. PLD, she developed prolonged grade 2 fatigue, grade 3 anemia, grade 3 neutropenia, and grade 2 lethargy. Nevertheless, there was an improvement in visual acuity and ambulation plus resolution of her headaches and eye ptosis. A repeat brain MRI showed a decrease in size and enhancement of the supra-and infratentorial lesions and no new lesions. After she recuperated from toxicity, the i.t. trastuzumab was restarted at the dose of 40 mg every 3 weeks and was maintained for 8 months, during which her symptoms slowly improved, even with concomitant steroid withdrawal. Furthermore, new MRI/ positron emission tomography studies confirmed a remarkable response in both the spinal cord lesion and the brain LM. In July 2007, 10 months after i.t. trastuzumab was started, a new MRI showed an enlargement of the lesions in the supra-and infratentorial levels, even in the absence of new central nervous system (CNS) lesions or new symptoms. I.t. trastuzumab (40 mg) was continued every 3 weeks, adding i.t. thiotepa 10 mg. The treatment was overall well tolerated, except for one episode of right face Herpes zoster which rapidly resolved. After 6 months of continuous i.t. treatment at such doses, the i. HER-2-positive cancers have a higher rate of dissemination to CNS [2] . An aggressive treatment on the CNS involvement was particularly justified in our patient, given that the disease was systemically well controlled. Nevertheless, symptomatic dissemination to the leptomeninges usually carries a short-term prognosis [3] , and i.t. treatment in most cases has a minor impact [4] . Five reports of i.t. trastuzumab were published so far [5] [6] [7] [8] [9] . I.t. thiotepa [5] or methotrexate [8] was also given in two cases. Our report offers further evidence on the safety of i.t. Annals of Oncology letters to the editor trastuzumab and strongly suggests that this approach can have a significant impact on HER-2-positive LM: our patient is alive and with an excellent performance status (Eastern Cooperative Oncology Group 0) after >2 years since the diagnosis of heavily symptomatic LM. During this time, she has been almost continuously treated with i.t. trastuzumab, efficiently delivered using an Ommaya reservoir. Initially, it was particularly difficult to evaluate the effectiveness of the treatment, as symptoms took several months to clearly improve, even if CSF cytology became negative after the first i.t. injection. The positive results of the first MRI led us to continue the i.t. treatment, even in the presence of an ambiguous clinical evolution. This suggests that MRI imaging could be the best single parameter to evaluate treatment efficacy and to predict a clinical benefit.
Our experience suggests that it is safe to combine i.t. trastuzumab with systemic trastuzumab-based chemotherapy regimens. Our patient had more side-effects with concomitant liposomal doxorubicin, given shortly after radiotherapy to the spine and when her performance status was still poor, while concomitant weekly schedules of vinorelbine or paclitaxel with i.v. trastuzumab were both characterized by a remarkable lack of toxicity. It is not possible to distinguish between the effect of i.t. and i.v. treatments on our patient's CNS metastases, but most likely the i.t. treatment had a major role in achieving long-term control of meningeal disease. Trastuzumab is unable to cross the blood-brain barrier [10] , and even after neurosurgery and radiotherapy, the i.t. concentration of trastuzumab is significantly lower than the serum concentration. Significantly higher levels can be achieved through i.t. administration [6] .
The combination of i.t. trastuzumab with thiotepa is particularly promising. We suggest that 50 mg of i.t. trastuzumab and 12 mg of i.t. thiotepa can be safely administered in repeated 3-week cycles. A number of preclinical studies showed a significant synergism between these two agents [11] . Indeed, after progression on single-agent i.t. trastuzumab, the LM in our patients were controlled with the addition of thiotepa, and the most relevant radiological response was reported after an increase of the i.t. doses of both drugs. No steroid was given at this time and thus this is not a confounding factor in the response to the treatment.
Even if meningeal carcinomatosis is not accurately 'measurable', as per RECIST criteria, this is one of few reports of a radiological response of meningeal metastases to a medical treatment, associated with the longest survival reported with i.t. trastuzumab after diagnosis of LM.
